WO2023204603A1 - Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait de complexe d'herbes médicinales en tant que principe actif - Google Patents

Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait de complexe d'herbes médicinales en tant que principe actif Download PDF

Info

Publication number
WO2023204603A1
WO2023204603A1 PCT/KR2023/005308 KR2023005308W WO2023204603A1 WO 2023204603 A1 WO2023204603 A1 WO 2023204603A1 KR 2023005308 W KR2023005308 W KR 2023005308W WO 2023204603 A1 WO2023204603 A1 WO 2023204603A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
coronavirus
composition
extract
Prior art date
Application number
PCT/KR2023/005308
Other languages
English (en)
Korean (ko)
Inventor
권선오
진영희
이상명
김상현
윤지원
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2023204603A1 publication Critical patent/WO2023204603A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • the present invention relates to a composition for preventing, improving, or treating coronavirus infection comprising a complex herbal medicine extract, particularly an extract of Gwakhyangjeonggisan, as an active ingredient.
  • the new type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2) is a virus that has a single-stranded positive RNA genome consisting of approximately 30,000 base pairs, and the viral surface is surrounded by an envelope. Since it was first reported in Wuhan, China at the end of December 2019, the number of infected people has rapidly increased worldwide. The virus spreads so efficiently between people that the World Health Organization has declared it a pandemic with the potential to spread around the world and is seeking responses.
  • Typical Covid-19 patients show relatively mild symptoms such as increased body temperature, cough, and chest pain, but some patients develop serious diseases such as difficulty breathing and pneumonia, leading to death.
  • coronavirus infections include ribavirin, famciclovir, nitazoxanide, nafamostat, and chloroquine.
  • Remdesi Remdesivir (GS-5734) and favipiravir are being used to treat coronavirus infections, but their effectiveness is low and the incidence of variant viruses is high due to the nature of nucleic acid analog antivirals, so two or more types of antivirals are applied together. .
  • Most antiviral drugs used for coronavirus infections have the ability to inhibit RNA polymerase, but mouse hepatitis virus, a type of coronavirus that is resistant to remdesivir, has been discovered, and existing antiviral drugs have been discovered. Viral drugs are ineffective.
  • antiviral drugs developed to date have severe side effects, so great caution is required in their application.
  • Korean Patent Publication No. 2022-0013625 discloses an anti-coronavirus composition characterized by containing an extract of Ulgoebul tree as an active ingredient
  • Korean Patent Publication No. 2022-0018953 discloses an anti-coronavirus composition containing fern extract or a fraction thereof.
  • the present invention was developed in response to the above-mentioned needs, and provides an antiviral composition for coronavirus containing an extract of Gwakhyangjeonggisan as an active ingredient, wherein the extract protects cells from coronavirus infection and inhibits virus proliferation.
  • the present invention was completed by confirming that it inhibits and reduces the mortality rate due to infection in a coronavirus infection animal model.
  • the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
  • the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the present invention relates to a composition for preventing, ameliorating or treating coronavirus infection comprising an extract of Kwak Hyang Jeong Gi Acid as an active ingredient.
  • the extract of Kwak Hyang Jeong Gi Acid protects cells from coronavirus infection, inhibits the proliferation of viruses, and prevents the spread of coronavirus. It is effective in reducing the mortality rate due to infection in animal models of viral infection.
  • Figure 1 shows the results of confirming the antiviral effect of Kwak Hyangjeonggi acid extract against SARS-CoV2 through CPE (Cytopathic effect) inhibition analysis.
  • (A) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with Gwakhyangjeonggisan extract at each concentration
  • (B) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with remdesivir, a positive control. This is one result.
  • NC is the normal group
  • VC is the control group treated with SARS-CoV2.
  • Figure 2 is a fluorescence photograph (A) confirming the viral infection inhibition effect of Kwak Hyangjeonggi acid extract on SARS-CoV2 and the result of quantifying it (B).
  • NC is the normal group
  • VC is the control group treated with SARS-CoV2.
  • Figure 3 shows the results of confirming body weight (A), body temperature (B), and survival rate (C) according to administration of Gwakhyangjeonggisan extract in a SARS-CoV2 infection animal model.
  • Mock is a normal group not infected with SARS-CoV2
  • Control is a SARS-CoV2 infected group.
  • the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
  • the coronavirus may be one or more types selected from the group consisting of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (SARS CoV), and Middle East respiratory syndrome (MERS) coronavirus, Preferably, it is type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2), but is not limited thereto.
  • SARS-CoV2 severe acute respiratory syndrome coronavirus
  • SARS CoV severe acute respiratory syndrome coronavirus
  • SARS CoV severe acute respiratory syndrome coronavirus
  • MERS Middle East respiratory syndrome
  • the extraction solvent of the Kwak Hyangjeonggi acid extract is preferably water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably water, but is not limited thereto.
  • the Kwakhyangjeonggisan may be a mixture of Kwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla, ginger and jujube, preferably 150 ⁇ 250 parts by weight of Gwakhyang, 80 ⁇ 170 parts by weight of perilla leaf, 50 ⁇ 80 parts by weight of Baekji, 50 ⁇ 80 parts by weight of Daebokpi, 50 ⁇ 80 parts by weight of Bokryeong, 50 ⁇ 80 parts by weight of Hubak, 50 ⁇ 80 parts by weight of Baekchul, It may be a mixture of 50 to 80 parts by weight of dermis, 50 to 80 parts by weight of Banha, 50 to 80 parts by weight of Gilt, 50 to 80 parts by weight of perilla root, 30 to 70 parts by weight of ginger and 50 to 90 parts by weight of jujube, and is more preferred.
  • the extract of Kwak Hyangjeonggi acid of the present invention has the effect of inhibiting the proliferation of type 2 severe acute respiratory syndrome coronavirus.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the pharmaceutical composition according to the present invention can be formulated and used in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. You can.
  • the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate. , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the pharmaceutical composition. It is prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc.
  • Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
  • As a base for suppositories wethepsol, macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used.
  • the appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically on the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.
  • the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • composition may be manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
  • the health functional food composition of the present invention When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods.
  • the amount of active ingredient can be appropriately used depending on the purpose of use (prevention or improvement).
  • the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the total raw materials.
  • the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • Health functional foods There are no particular restrictions on the types of health functional foods. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. There are drinks, alcoholic beverages, and vitamin complexes, and it includes all health foods in the conventional sense.
  • the health functional food composition of the present invention can be manufactured into food, especially functional food.
  • the functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings.
  • ingredients commonly added during food production includes, for example, proteins, carbohydrates, fats, nutrients and seasonings.
  • natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient.
  • the natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., For example, xylitol, sorbitol, erythritol, etc.) is preferable.
  • the flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
  • the ratio of the ingredients added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
  • the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
  • the quasi-drugs may include external skin preparations and personal hygiene products.
  • it may be a disinfectant cleaner, shower foam, garnish, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
  • the composition can be added as is or used with other quasi-drugs or quasi-drug components, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
  • the quasi-drug composition of the present invention may be manufactured in the form of a general emulsified formulation or solubilized formulation.
  • it may have a formulation such as lotion, cream, ointment, spray, oil gel, gel, oil, or aerosol, but can be used without limitation as long as it shows the effect of preventing or improving the coronavirus infection of the present invention. there is.
  • the quasi-drug composition contains oil, water, surfactants, moisturizers, lower alcohols with 1 to 4 carbon atoms, thickeners, chelating agents, colorants, preservatives or fragrances, etc., which are generally mixed in quasi-drug compositions, as appropriate for each dosage form. Can be used in combination.
  • the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, conventional auxiliaries such as pigments and fragrances, and carriers.
  • the cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing products. , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be manufactured in the form of flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, shampoo, pack, spray or powder. You can.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacantha, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
  • the formulation of the present invention is a powder or spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient.
  • chlorofluorohydrocarbon and propane may be used as carrier ingredients.
  • May contain propellants such as butane or dimethyl ether.
  • a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
  • the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystals.
  • a liquid diluent such as ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • microcrystals ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • Cellulose, aluminum metahydroxide, bentonite, agar or tragacantha can be used.
  • the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide.
  • Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.
  • the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.
  • the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals.
  • the type of feed is not particularly limited, and feed commonly used in the art can be used.
  • Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products;
  • animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.
  • Gwakhyangjeonggisan extract of the present invention used in the extract of Gwakhyangjeonggisan, Gwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla perilla, ginger and jujube were purchased as standard products from Dongwoodang Pharmaceutical, weighing 189.1g.
  • the Kwakhyangjeonggi acid extract of the present invention protects cells from the SARS-CoV2 virus and kills the virus.
  • the antiviral effect of inhibiting proliferation was excellent.
  • Vero E6 cells were distributed in a 96 -well plate at 1 SARS-CoV2 diluted 1000 times with DMEM was treated and then cultured for 24 hours. After incubation, the cells were fixed with a 4% (v/v) formaldehyde solution, reacted with a primary antibody (N-protein) diluted 2000 times, and then reacted with a secondary antibody diluted 200 times. After the reaction, the cells were observed under a fluorescence microscope, and the fluorescence intensity was analyzed.
  • the body weight of the group administered the Kwak Hyangjeonggi acid extract of the present invention was slightly increased compared to the SARS-CoV2 infection group after the 6th day, and the body temperature of the SARS-CoV2 infection group was 6 days.
  • the group administered the Kwak Hyang Jeong-ki acid extract of the present invention maintained body temperature at a level similar to that of the normal group, and the survival rate of the SARS-CoV2 infection group on day 10 decreased sharply, but the The survival rate of the extract administered group was maintained at about 60%. Therefore, it was determined that the Kwak Hyangjeonggi acid extract of the present invention can reduce the mortality rate of the severe SARS-CoV2 infection group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir, atténuer ou traiter une infection à coronavirus, contenant un extrait de Gwakhyanggunggisan en tant que principe actif. L'extrait de Gwakhyanggunggisan présente d'excellents effets de protection des cellules contre une infection à coronavirus, d'inhibition de la prolifération des virus et de réduction du taux de mortalité provoqué par une infection sur des modèles animaux infectés par un coronavirus, et ainsi la composition de la présente invention, comprenant l'extrait de Gwakhyanggunggisan en tant que principe actif, peut être efficacement utilisée en tant qu'agent pour traiter une infection à coronavirus, en tant qu'alicament anticoronavirus, en tant que quasi-médicament, en tant que produit cosmétique ou en tant qu'additif alimentaire.
PCT/KR2023/005308 2022-04-20 2023-04-19 Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait de complexe d'herbes médicinales en tant que principe actif WO2023204603A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220048912A KR102527037B1 (ko) 2022-04-20 2022-04-20 복합한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR10-2022-0048912 2022-04-20

Publications (1)

Publication Number Publication Date
WO2023204603A1 true WO2023204603A1 (fr) 2023-10-26

Family

ID=86387545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/005308 WO2023204603A1 (fr) 2022-04-20 2023-04-19 Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait de complexe d'herbes médicinales en tant que principe actif

Country Status (2)

Country Link
KR (1) KR102527037B1 (fr)
WO (1) WO2023204603A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210112570A (ko) * 2020-03-05 2021-09-15 남종현 항 전염성 위장염 바이러스(tgev)용 조성물 및 이를 포함하는 약학 조성물
KR20220018919A (ko) * 2020-08-07 2022-02-15 기초과학연구원 길경 추출물을 포함하는 외막형 바이러스(enveloped viruses)의 예방 및 치료용 약학 조성물
KR20220044082A (ko) * 2020-09-28 2022-04-06 한국 한의학 연구원 천연물 혼합 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210112570A (ko) * 2020-03-05 2021-09-15 남종현 항 전염성 위장염 바이러스(tgev)용 조성물 및 이를 포함하는 약학 조성물
KR20220018919A (ko) * 2020-08-07 2022-02-15 기초과학연구원 길경 추출물을 포함하는 외막형 바이러스(enveloped viruses)의 예방 및 치료용 약학 조성물
KR20220044082A (ko) * 2020-09-28 2022-04-06 한국 한의학 연구원 천연물 혼합 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANG BO-HYUNG, CHOI YOU-KYOUNG, JEON CHAN-YONG, YANG SEUNG-BO: "The Effects of Qingfei Paidu Decoction on Coronavirus Disease-19: A Narrative Review", THE KOREAN SOCIETY FOR ORIENTAL INTERNAL MEDICINE, KOREAN INTELLECTUAL PROPERTY OFFICE, vol. 41, no. 3, 30 June 2020 (2020-06-30), pages 424 - 433, XP093101027, ISSN: 1226-9174, DOI: 10.22246/jikm.2020.41.3.424 *
LEE JONG-HOON: "Corona treatment herbal medicine 6 Kwakhyangjeonggisan prescription explanation: Naver blog", BLOG DR. JONG-HOON LEE, 25 January 2022 (2022-01-25), XP093100694, Retrieved from the Internet <URL:https://m.blog.naver.com/yijonghoon/222631029583> [retrieved on 20231113] *

Also Published As

Publication number Publication date
KR102527037B1 (ko) 2023-05-02

Similar Documents

Publication Publication Date Title
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
WO2020013610A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement de maladies cutanées allergiques, contenant, en tant que principe actif, un extrait de fruits de gardénia desquels des pigments sont retirés
WO2023249392A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, contenant un extrait d&#39;herbe médicinale utilisé en tant que principe actif
WO2023249393A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, contenant un extrait d&#39;herbe médicinale utilisé en tant que principe actif
KR102187951B1 (ko) 녹각 영지버섯 추출물 및 퀘르세틴을 유효성분으로 포함하는 엡스타인 바 바이러스-양성 위암 치료용 약학적 조성물
KR102540814B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
WO2011055931A2 (fr) Composition destinée à prévenir ou à traiter des maladies provoquées par les virus de la grippe
WO2023204603A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, contenant un extrait de complexe d&#39;herbes médicinales en tant que principe actif
EP0297547A2 (fr) Emploi de tannates hydrolysables pour le traitement et la prophylaxie du SIDA
WO2023204602A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, comprenant un extrait de complexe d&#39;herbes médicinales en tant que principe actif
WO2023200289A1 (fr) Composition pour la prévention, l&#39;atténuation ou le traitement d&#39;une infection à coronavirus, contenant un extrait d&#39;herbe médicinale utilisé en tant que principe actif
KR102578871B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102676865B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102540384B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102526308B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102529571B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102533344B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102524075B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102506856B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102512522B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102524078B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102532944B1 (ko) 복합한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102499066B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102546110B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR102524083B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23792177

Country of ref document: EP

Kind code of ref document: A1